Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Npt2b deletion attenuates hyperphosphatemia associated with CKD.

Schiavi SC, Tang W, Bracken C, O'Brien SP, Song W, Boulanger J, Ryan S, Phillips L, Liu S, Arbeeny C, Ledbetter S, Sabbagh Y.

J Am Soc Nephrol. 2012 Oct;23(10):1691-700. Epub 2012 Aug 2.

2.

Role of NPT2b in health and chronic kidney disease.

Sabbagh Y, Schiavi SC.

Curr Opin Nephrol Hypertens. 2014 Jul;23(4):377-84. doi: 10.1097/01.mnh.0000447015.44099.5f. Review.

PMID:
24848935
3.

Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.

Navaneethan SD, Palmer SC, Craig JC, Elder GJ, Strippoli GF.

Am J Kidney Dis. 2009 Oct;54(4):619-37. doi: 10.1053/j.ajkd.2009.06.004. Epub 2009 Aug 18. Review.

PMID:
19692157
4.

Inorganic phosphate homeostasis in sodium-dependent phosphate cotransporter Npt2b⁺/⁻ mice.

Ohi A, Hanabusa E, Ueda O, Segawa H, Horiba N, Kaneko I, Kuwahara S, Mukai T, Sasaki S, Tominaga R, Furutani J, Aranami F, Ohtomo S, Oikawa Y, Kawase Y, Wada NA, Tachibe T, Kakefuda M, Tateishi H, Matsumoto K, Tatsumi S, Kido S, Fukushima N, Jishage K, Miyamoto K.

Am J Physiol Renal Physiol. 2011 Nov;301(5):F1105-13. doi: 10.1152/ajprenal.00663.2010. Epub 2011 Aug 3.

5.

Effect of a non-calcium-based phosphate binder on fibroblast growth factor 23 in chronic kidney disease.

Spatz C, Roe K, Lehman E, Verma N.

Nephron Clin Pract. 2013;123(1-2):61-6. doi: 10.1159/000351811. Epub 2013 Jun 14.

6.

Effects of phosphate on vascular function under normal conditions and influence of the uraemic state.

Six I, Maizel J, Barreto FC, Rangrez AY, Dupont S, Slama M, Tribouilloy C, Choukroun G, Mazière JC, Bode-Boeger S, Kielstein JT, Drüeke TB, Massy ZA.

Cardiovasc Res. 2012 Oct 1;96(1):130-9. doi: 10.1093/cvr/cvs240. Epub 2012 Jul 20.

PMID:
22822101
7.

[Pleiotropic effects of sevelamer: a model of intestinal tract chelating agent].

Massy ZA, Maizel J.

Nephrol Ther. 2014 Nov;10(6):441-50. doi: 10.1016/j.nephro.2014.04.001. Epub 2014 Jul 26. Review. French.

PMID:
25070605
8.

Osteo-renal regulation of systemic phosphate metabolism.

Razzaque MS.

IUBMB Life. 2011 Apr;63(4):240-7. doi: 10.1002/iub.437. Epub 2011 Mar 24. Review.

9.

Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.

Molony DA, Stephens BW.

Adv Chronic Kidney Dis. 2011 Mar;18(2):120-31. doi: 10.1053/j.ackd.2011.02.004. Review.

PMID:
21406297
10.

Reversal of the adynamic bone disorder and decreased vascular calcification in chronic kidney disease by sevelamer carbonate therapy.

Mathew S, Lund RJ, Strebeck F, Tustison KS, Geurs T, Hruska KA.

J Am Soc Nephrol. 2007 Jan;18(1):122-30. Epub 2006 Dec 20.

11.

A comparison of calcium acetate/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a controlled, randomized study.

Covic A, Passlick-Deetjen J, Kroczak M, Büschges-Seraphin B, Ghenu A, Ponce P, Marzell B, de Francisco AL.

Nephrol Dial Transplant. 2013 Sep;28(9):2383-92. doi: 10.1093/ndt/gft203. Epub 2013 Jun 19.

12.

Lanthanum carbonate, like sevelamer-HCl, retards the progression of vascular calcification and atherosclerosis in uremic apolipoprotein E-deficient mice.

Nikolov IG, Joki N, Nguyen-Khoa T, Guerrera IC, Maizel J, Benchitrit J, Machado dos Reis L, Edelman A, Lacour B, Jorgetti V, Drüeke TB, Massy ZA.

Nephrol Dial Transplant. 2012 Feb;27(2):505-13. doi: 10.1093/ndt/gfr254. Epub 2011 Jun 24.

PMID:
21705467
13.

Effect of a magnesium-based phosphate binder on medial calcification in a rat model of uremia.

De Schutter TM, Behets GJ, Geryl H, Peter ME, Steppan S, Gundlach K, Passlick-Deetjen J, D'Haese PC, Neven E.

Kidney Int. 2013 Jun;83(6):1109-17. doi: 10.1038/ki.2013.34. Epub 2013 Mar 13.

14.

The pathophysiology of early-stage chronic kidney disease-mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat.

Moe SM, Radcliffe JS, White KE, Gattone VH 2nd, Seifert MF, Chen X, Aldridge B, Chen NX.

J Bone Miner Res. 2011 Nov;26(11):2672-81. doi: 10.1002/jbmr.485.

15.

Phosphate restriction significantly reduces mortality in uremic rats with established vascular calcification.

Finch JL, Lee DH, Liapis H, Ritter C, Zhang S, Suarez E, Ferder L, Slatopolsky E.

Kidney Int. 2013 Dec;84(6):1145-53. doi: 10.1038/ki.2013.213. Epub 2013 Oct 9.

PMID:
24107846
16.

Sevelamer carbonate: a review in hyperphosphataemia in adults with chronic kidney disease.

Perry CM, Plosker GL.

Drugs. 2014 May;74(7):771-92. doi: 10.1007/s40265-014-0215-7. Review.

PMID:
24811546
17.

Bixalomer, a novel phosphate binder with a small swelling index, improves hyperphosphatemia in chronic kidney disease rat.

Taniguchi K, Kakuta H.

Eur J Pharmacol. 2015 Nov 5;766:129-34. doi: 10.1016/j.ejphar.2015.10.001. Epub 2015 Oct 9.

PMID:
26452517
18.

Disturbances of Wnt/β-catenin pathway and energy metabolism in early CKD: effect of phosphate binders.

de Oliveira RB, Graciolli FG, dos Reis LM, Cancela AL, Cuppari L, Canziani ME, Carvalho AB, Jorgetti V, Moysés RM.

Nephrol Dial Transplant. 2013 Oct;28(10):2510-7. doi: 10.1093/ndt/gft234. Epub 2013 Aug 23.

PMID:
23975746
19.

Mutant FGF23 prevents the progression of chronic kidney disease but aggravates renal osteodystrophy in uremic rats.

Kusano K, Saito H, Segawa H, Fukushima N, Miyamoto K.

J Nutr Sci Vitaminol (Tokyo). 2009 Apr;55(2):99-105.

20.

Effect of manipulating serum phosphorus with phosphate binder on circulating PTH and FGF23 in renal failure rats.

Nagano N, Miyata S, Abe M, Kobayashi N, Wakita S, Yamashita T, Wada M.

Kidney Int. 2006 Feb;69(3):531-7.

Supplemental Content

Support Center